肾结石 中国就医指南

Nephrolithiasis, commonly known as kidney stones, is a prevalent urological and nephrological disorder characterized by the formation of solid crystalline aggregates within the renal collecting system or urinary tract. These stones originate from supersaturation of urine with stone-forming substances—primarily calcium oxalate (75–80%), calcium phosphate, uric acid, struvite (magnesium ammonium phosphate), or cystine—and insufficient inhibitors of crystallization such as citrate, magnesium, and Tamm-Horsfall protein. Pathogenesis involves a complex interplay of metabolic, anatomical, dietary, and genetic factors: hypercalciuria, hyperoxaluria, hypocitraturia, low urine volume, urinary pH abnormalities, and recurrent urinary tract infections (especially with urease-producing bacteria) all contribute to nucleation, crystal growth, aggregation, and retention. Epidemiologically, nephrolithiasis affects approximately 8–12% of the global population, with higher prevalence in North America, Europe, and parts of Asia—including China, where incidence has risen steadily over the past two decades due to urbanization, dietary shifts (increased sodium, animal protein, and sugar-sweetened beverage consumption), and sedentary lifestyles. Men are affected 2–3 times more frequently than women, though the gender gap narrows after age 50. Peak incidence occurs between ages 30 and 50. Key modifiable risk factors include chronic dehydration, high dietary sodium and purine intake, obesity, metabolic syndrome, diabetes mellitus, gout, inflammatory bowel disease, and certain medications (e.g., loop diuretics, topiramate, calcium-based antacids). Non-modifiable risks include family history, prior stone episodes (recurrence rate exceeds 50% within 5 years without intervention), and anatomical abnormalities like medullary sponge kidney. Beyond acute morbidity—such as excruciating colic, hematuria, nausea, vomiting, and urinary obstruction—nephrolithiasis significantly impairs quality of life: patients report anxiety around recurrence, activity limitations, sleep disruption, work absenteeism, and diminished mental well-being. Chronic complications may include recurrent urinary tract infections, obstructive nephropathy, hypertension, and progressive chronic kidney disease—particularly with staghorn calculi or bilateral obstruction. Early diagnosis via non-contrast CT (gold standard), ultrasound, or KUB radiography, coupled with comprehensive metabolic evaluation (24-hour urine chemistry, serum electrolytes, uric acid, parathyroid hormone), enables personalized prevention strategies including dietary counseling, fluid optimization (>2 L/day urine output), and targeted pharmacotherapy (thiazides, potassium citrate, allopurinol, or cystine-binding agents). Multidisciplinary care involving nephrologists, urologists, dietitians, and metabolic specialists is essential for long-term management and recurrence reduction.

# 肾结石治疗方案与详细费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：结石≤6mm、无梗阻/感染、肾功能正常者

• •药物排石（α受体阻滞剂+解痉镇痛）：盐酸坦索罗辛+曲马多，疗程2–4周，药费 180–450元
• •水化促排：每日饮水≥2000mL，配合尿液pH监测（试纸/便携pH仪），耗材费 30–120元
• •检查检验费：泌尿系超声（120元）、尿常规+尿培养（85元）、血肌酐+电解质（95元）、24h尿钙/尿酸定量（260元）

二、手术/微创介入方案

适用人群：结石＞6mm、伴轻中度积水、单侧或双侧结石需分次处理

• •体外冲击波碎石（ESWL）：单次治疗，含定位超声+碎石，2800–4200元（含术前CT平扫180元）
• •输尿管镜碎石取石术（URS）：钬激光碎石，含麻醉、耗材（镜体/导丝/套石篮），12,500–18,600元（术前增强CT 380元）
• •经皮肾镜碎石取石术（PCNL）：复杂鹿角形/多发结石，含穿刺建鞘、钬激光、术后双J管置入，24,800–36,000元（含术前MRI尿路成像MRU 850元）

三、特殊复杂情况方案

适用人群：合并脓肾、孤立肾结石、遗传性高草酸尿症、ESWL/URS失败≥2次

• •多学科联合根治（肾内科+泌尿外科+营养科）：代谢评估+个体化溶石方案（如枸橼酸钾长期治疗）+择期PCNL，总费用 42,000–78,000元（含基因检测2600元、3个月随访管理费1200元）

四、方案快速选择指南

• •预算＜5000元+结石＜5mm → 保守治疗+定期超声随访
• •预算1.5–3万元+单发6–20mm输尿管上段结石 → 首选URS
• •预算＞4万元+鹿角形/多发/孤立肾结石 → PCNL联合代谢干预
• •反复发作+家族史 → 必查24h尿代谢分析+遗传筛查，启动长期预防管理